Search

BioCryst Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

9.66 1.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.48

Max

9.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

800M

78M

Verkäufe

62M

218M

KGV

Branchendurchschnitt

7.603

57.371

EPS

0.3

Gewinnspanne

35.92

Angestellte

435

EBITDA

799M

99M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+114.03% upside

Dividenden

By Acuity

Nächstes Ergebnis

2. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

301M

2.5B

Vorheriger Eröffnungskurs

8.51

Vorheriger Schlusskurs

9.66

BioCryst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Aug. 2026, 19:26 UTC

BioCryst Pharmaceuticals Inc shares are trading higher, maintaining a position above the 20-day moving average and near the midpoint of their one-month range.

21. Aug. 2026, 22:26 UTC

BioCryst Pharmaceuticals shares moved higher in after-hours trading, reaching a session high before slightly retracing. No specific news was identified to explain the movement.

20. Aug. 2026, 20:01 UTC

Correlated Moves
Social Media

BioCryst Pharmaceuticals Inc shares are lower amid a decline in the Biotechnology sub-sector. Earlier in the session, shares rebounded from a session high.

19. Aug. 2026, 23:01 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, retracing from an earlier uptick with no specific news identified to explain the decline.

18. Aug. 2026, 20:06 UTC

BioCryst Pharmaceuticals Inc shares are declining amid broader market weakness, with no specific news identified to explain today's price movement.

14. Aug. 2026, 19:06 UTC

BioCryst Pharmaceuticals is lower today, following broader market concerns over an unexpected drop in U.S. retail sales impacting Federal Reserve interest rate policy.

13. Aug. 2026, 21:31 UTC

BioCryst Pharmaceuticals shares traded roughly flat in after-market hours, remaining within their one-month range and above the 20-day moving average.

12. Aug. 2026, 19:41 UTC

BioCryst Pharmaceuticals shares are higher today, rebounding from an earlier dip and reflecting notable volatility during the session. The stock remains above its 20-day moving average.

11. Aug. 2026, 23:26 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid broader market weakness and cautious sentiment.

10. Aug. 2026, 19:51 UTC

News

BioCryst Pharmaceuticals Inc. shares are higher after Wall Street Zen upgraded its rating to "strong-buy." Other firms also adjusted price targets amid market uncertainty.

7. Aug. 2026, 19:56 UTC

BioCryst Pharmaceuticals is trading higher, continuing a positive trend amid easing concerns over interest rate hikes following a disappointing jobs report.

6. Aug. 2026, 22:36 UTC

BioCryst Pharmaceuticals shares are lower in after-market trading, continuing a decline since Thursday's close and positioned below the 20-day moving average.

5. Aug. 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, despite no specific news identified to explain the movement. They remain below their 20-day moving average.

4. Aug. 2026, 19:36 UTC

Correlated Moves

BioCryst Pharmaceuticals Inc shares are higher today, supported by gains in the biotechnology sector. The stock remains above its earlier low despite recent trends.

3. Aug. 2026, 19:56 UTC

BioCryst Pharmaceuticals Inc shares are lower today, continuing a downward trend since Friday. The broader market is seeing gains, contrasting with BioCryst's performance.

31. Juli 2026, 22:36 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading. No specific news was identified to explain this movement, reflecting routine performance since Friday's close.

30. Juli 2026, 20:09 UTC

BioCryst Pharmaceuticals shares are lower amid broader market volatility following mixed economic signals, including rising jobless claims and disappointing GDP growth.

29. Juli 2026, 19:35 UTC

BioCryst Pharmaceuticals Inc shares are lower amid a declining market, with no specific company news identified to explain the movement during today's session.

28. Juli 2026, 23:06 UTC

BioCryst Pharmaceuticals Inc shares are higher in after-market trading, continuing an upward trend from Tuesday's close, despite an earlier session pullback.

27. Juli 2026, 20:01 UTC

BioCryst Pharmaceuticals Inc shares are trading higher in Monday's session, reflecting notable strength despite remaining near the lower end of their one-month trading range.

24. Juli 2026, 21:01 UTC

BioCryst Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market trends following a decline in the Nasdaq influenced by negative earnings reports.

22. Juli 2026, 21:51 UTC

BioCryst Pharmaceuticals Inc shares are lower in after-market trading, continuing a decline amid significant volatility in U.S. markets and lack of specific news.

21. Juli 2026, 17:46 UTC

BioCryst Pharmaceuticals Inc shares are higher today, continuing an upward trend since Monday. The stock remains below its 20-day moving average.

20. Juli 2026, 19:16 UTC

Correlated Moves

Shares lower amid decline in Biotechnology sub-sector and SPDR ETF.

Peer-Vergleich

Kursveränderung

BioCryst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

114.03% Vorteil

12-Monats-Prognose

Durchschnitt 20.44 USD  114.03%

Hoch 32 USD

Tief 12 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioCryst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
help-icon Live chat